Establishment and characterization of allograft and xenograft cancer rodent models
Date
2019Author
Koatale, Palesa
Okem, Ambrose
Venter, Kobus
Fick, Antoinette
Bester, Cor
Hayeshi, Rose
Metadata
Show full item recordAbstract
To evaluate the efficacy of newly synthesized therapies prior to
clinical trials, valid and true cancer models should be used [1]. For
modelling cancer in vivo, transplantation of rodent (allograft) and
human cancer cells (xenograft) in immune-competent and immunedeficient mice, respectively is common [2]. The aim of this study was
to develop and characterize breast cancer allograft and human
ovarian xenograft cancer rodent models. The allograft model was
established by injection of E0771 cells suspended in Matrigel,
subcutaneously into the mammary fat pad of female C57BL/6 mice.
For xenograft model, human OVCAR-3 cells suspended in Matrigel
were injected subcutaneously into the hind flank of athymic nude
female mice. Once a tumor was palpable, tumor growth was
monitored 2–3 times a week using a digital caliper and the animals
were euthanized once tumor volume of ≥300 mm3 was attained.
Finally, haematoxylin and eosin staining of the tumors was
conducted to confirm malignancy. For the E0771 derived allograft
model (Fig. 1), tumors were detectable within a week post
inoculation with a tumor take rate of 14/14 (100%). For OVCAR-3
derived xenograft model (Figure1B), tumors were detected approximately 5 weeks post inoculation with tumor take rate of 3/4
(75%). Histological analysis of both models revealed mitotic figures
indicating that the tumors were actively proliferating and malignant.
The rodent models of breast and ovarian cancer were successfully
established and characterized and; can be used to evaluate novel
clinical compounds and formulations
URI
http://hdl.handle.net/10394/33317https://www.sciencedirect.com/science/article/pii/S1056871919303260
https://doi.org/10.1016/j.vascn.2019.106608